---
title: "Investing in Insulet (NASDAQ:PODD) a year ago would have delivered you a 47% gain"
description: "Investing in Insulet (NASDAQ:PODD) a year ago would have yielded a 47% gain, outperforming the market's 10% return. Despite this, the stock's long-term performance shows only a 25% increase over three"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238683806.md"
published_at: "2025-05-04T16:31:35.000Z"
---

# Investing in Insulet (NASDAQ:PODD) a year ago would have delivered you a 47% gain

> Investing in Insulet (NASDAQ:PODD) a year ago would have yielded a 47% gain, outperforming the market's 10% return. Despite this, the stock's long-term performance shows only a 25% increase over three years. Insulet's earnings per share (EPS) grew by 102% in the last year, indicating that the share price has not kept pace with its growth. While recent returns are promising, the overall annualized return over the past five years stands at just 3%. Investors are encouraged to consider the company's balance sheet and insider trading activities before making decisions.

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can significantly boost your returns by picking above-average stocks. For example, the **Insulet Corporation** (NASDAQ:PODD) share price is up 47% in the last 1 year, clearly besting the market return of around 10% (not including dividends). So that should have shareholders smiling. Having said that, the longer term returns aren't so impressive, with stock gaining just 25% in three years.

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

In his essay *The Superinvestors of Graham-and-Doddsville* Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the last year Insulet grew its earnings per share (EPS) by 102%. It's fair to say that the share price gain of 47% did not keep pace with the EPS growth. So it seems like the market has cooled on Insulet, despite the growth. Interesting.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

It is of course excellent to see how Insulet has grown profits over the years, but the future is more important for shareholders. If you are thinking of buying or selling Insulet stock, you should check out this **FREE** detailed report on its balance sheet.

## A Different Perspective

We're pleased to report that Insulet shareholders have received a total shareholder return of 47% over one year. That's better than the annualised return of 3% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. If you would like to research Insulet in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this **free** list of companies that have proven they can grow earnings.

*Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.*

If you're looking to trade Insulet, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

### Related Stocks

- [PODD.US - Insulet](https://longbridge.com/en/quote/PODD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insulet｜10-K：2025 財年營收 27.08 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276270064.md) |
| Insulet｜8-K：2025 財年 Q4 營收 7.84 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276225181.md) |
| 05:52 ET 根據 Allied Market Research 的報告，全球人工胰腺設備系統市場預計到 2033 年將達到 8 億美元，年複合增長率為 8.8% | 全球人工胰腺設備系統市場預計將從 2023 年的 4 億美元增長到 2033 年的 8 億美元，年均增長率為 8.8%。這一增長受到 1 型糖尿病患病率上升、對自動化血糖管理需求增加以及技術進步的推動。北美因高採用率和有利政策而領先市場。主 | [Link](https://longbridge.com/en/news/276051514.md) |
| Insulet 在中東市場推出 Omnipod 5 和 Omnipod Discover | Insulet Corporation 已在沙特阿拉伯、科威特、卡塔爾和阿聯酋推出其 Omnipod 5 自動胰島素輸送系統和 Omnipod Discover 數據分析平台。這一擴展旨在改善中東地區的糖尿病管理，解決該地區顯著的未滿足需求 | [Link](https://longbridge.com/en/news/274967991.md) |
| Insulet 公司在最新的投資者演示中突出了其在糖尿病管理方面的領導地位以及市場增長 | Insulet Corporation 在摩根大通第 44 屆年度醫療會議上展示了其在糖尿病管理領域的領導地位。該公司強調了其獲得 FDA 批准的自動胰島素輸送（AID）系統，這是美國處方最多的系統。Insulet 預計 2025 年的收入 | [Link](https://longbridge.com/en/news/272454304.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
